azacitidine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barankiewicz, J; Basak, GW; Biecek, P; Drozd-Sokołowska, J; Karakulska-Prystupiuk, E; Kobylińska, K; Mądry, K; Rytel, J; Salomon-Perzyński, A; Skwierawska, K; Stokłosa, T | 1 |
| Boenisch, O; Bokemeyer, C; Fiedler, W; Ghandili, S; Ittrich, H; Jarczak, D; Karagiannis, P; Kluge, S; Lütgehetmann, M; Modemann, F; Pfefferle, S; Roedl, K; Rohde, H; Schmiedel, S; Sonnemann, P; Weisel, K; Wichmann, D | 1 |
2 other study(ies) available for azacitidine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; COVID-19; Female; Humans; Leukemia, Myeloid, Acute; Male; Pandemics; SARS-CoV-2 | 2023 |
Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; COVID-19; Cytarabine; Extracorporeal Membrane Oxygenation; Female; Humans; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2020 |